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WEB-ENABLED ASTHMA APPLICATION FOR PERSONALIZED
MEDICAL COMMUNICATION WITHIN A MULTI-GROUP
PRACTICE SETTING
Arnold RJ1, Kaniecki DJ1, Rosen J2
1Pharmacon International, Inc, New York, NY, USA; 2ProHealth
Physicians, Bristol, CT, USA
OBJECTIVES: 1) Integrate the Automated Live E-Health
Response Tracking System (ALERTS) disease management
program’s Internet platform with existing interactive voice
response (IVR) and other technologies; 2) Customize patient
templates for recording Peak Expiratory Flow measurements,
answering questionnaires that assess asthma symptoms and
severity, and receiving feedback to enhance asthma control; 3)
Customize provider templates to generate appropriate individu-
alized patient reports that can be retrieved on demand, enabling
better triage of asthmatic cases through rules-based triggers and
alerts; and 4) Deploy ALERTS to representative asthmatic
patients at ProHealth Physicians (PHP). METHODS: PHP
recruited 71 patients at 6 clinics. Patients signed informed
consent and accessed the program via their preferred method(s)
of communication. Overall acceptability of the program was
assessed using a participant satisfaction survey. Patients and
providers were paid for participating for a minimum of 3
months. RESULTS: The ALERTS program was initiated suc-
cessfully with 71 asthmatic patients of varying ages and disease
severity. Patients had indicated that they lacked a mechanism to
interact with their physician and nurses before and after the
ofﬁce visits (25% rarely, 25% frequently and 50% never inter-
act with health care providers) and 40% of them said they
received care in the Emergency Room at least once per year.
Although initially skeptical, the majority of patients and physi-
cians liked the program and were able to use it; 22% of patients
accessed the program via Internet and the remainder used IVR.
Qualitative analysis demonstrated that some patients who had
previously never been controlled were empowered and 30–50%
beneﬁted from the program, depending on the severity of their
asthma. CONCLUSION: The Asthma ALERTS program
addressed these issues by enhancing the participation and en-
gagement of patients and empowering them in self-management
of their asthma. Issues currently being addressed include incen-
tives for patient and physician participation and streamlining of
enrollment processes.
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INHALED SALMETEROL UTILIZATION AND ASTHMA
PATIENT OUTCOMES IN A GROUP-MODEL MANAGED 
CARE ORGANIZATION
Plauschinat CA1, Browne BA1, Godley PJ1,Weldon DR2
1Scott & White Memorial Hospital,Temple,TX, USA; 2Scott & White
Clinic in College Station, College Station,TX, USA
OBJECTIVE: To evaluate utilization and asthma patient out-
comes of inhaled salmeterol (long-acting beta-agonist [LABA])
alone and in combination with an inhaled corticosteroid (ICS)
in a group-model managed care organization (MCO).
METHODS: Using medical and pharmacy claims from a group-
model MCO with approximately 175,000 covered lives, patients
with a diagnosis of asthma receiving at least one inhaled salme-
terol prescription during a 9-month (October 1, 2000 to June
30, 2001) period were identiﬁed. Patients were stratiﬁed into two
groups, LABA and LABA/ICS, based on ICS utilization. Age,
short-acting beta-agonist (SABA) use, and asthma-related emer-
gency room (ER) visits and hospital admissions were assessed. A
literature-validated medication use index was used to classify
asthma severity. RESULTS: A total of 1025 asthma patients were
identiﬁed (mean age 49.2 years, 61% female). Approximately
28% of patients were in the LABA group and 72% in LABA/ICS
group. LABA/ICS patients were more likely to be greater than
19 years of age (87% vs. 82% in LABA group) and to receive a
SABA prescription during the study period (63% vs. 43%).
LABA/ICS patients had a disproportionate greater number of ER
visits (22 [3%]) in comparison to LABA patients (2 [0.7%]). No
hospitalizations were observed in either group. Regarding
asthma severity, LABA patients had less severe forms of asthma;
mild asthma (15% vs. 0% in LABA/ICS group), moderate
asthma (40% vs. 13%), and severe asthma (45% vs. 87%).
CONCLUSION: In comparison to inhaled salmeterol monother-
apy, the addition of an ICS was a marker for more severe forms
of asthma. Development of asthma quality improvement pro-
grams should consider this observation when evaluating asthma
severity.
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LOCAL ADVERSE EVENT RATES AND COSTS ASSOCIATED
WITH INHALED CORTICOSTEROIDS USE
Chow W1, Concetta C1, Szwarcberg J1, Lee D2, Patton M2,
Haberman M2, Goldberg G2, Broderick W2
1Aventis Pharmaceuticals, Bridgewater, NJ, USA; 2Constella Health
Strategies, Durham, NC, USA
OBJECTIVES: Inhaled corticosteroids (ICS) are an important
part of asthma treatment; however, their use is associated with
localized adverse events (LAEs). This study quantiﬁed LAE rates
and costs associated with ICS use in the community.
METHODS: We assembled a 1 :2 age/gender matched cohort of
asthmatics age >18 who did and did not initiate ICS using
1998–2002 administrative claims data from a large, US managed
care organization (N = 20,280). All ICS formulations were con-
sidered; patients were followed for one year, and were required
to have had no more than one oral or injectable steroid. LAEs
were deﬁned as dysphonia, oral candidiasis, throat irritation,
cough, upper respiratory infections and sinusitis. We compared
LAE rates in two cohorts stratiﬁed by asthma severity and
selected comorbidities; the incremental cost of a LAE was esti-
mated using multivariate regression that controlled for demo-
graphic characteristics, asthma severity, and selected comorbid
conditions. RESULTS: The LAE rate among ICS users was 2.2
percentage points (5.6%) higher than non-ICS users (41.2% vs.
39.0%, p < 0.01). LAE rates were similar in the two groups when
stratiﬁed by asthma severity, but were signiﬁcantly higher among
ICS users who had other comorbidities, compared to non-ICS
asthmatics with the same conditions. Asthmatics who experi-
enced a LAE had mean charges (exclusive of ICS prescriptions)
estimated 49% higher than asthmatics who did not after 
controlling for confounding (p < 0.03). Given sample non-ICS
median charges of $249 per-patient-per-month (PPPM), the esti-
mated cost of a LAE was $122PPPM (49% ¥ $249), and the
estimated cost of an ICS-induced LAE was $2.68 PPPM (2.2%
¥ $122). CONCLUSIONS: Our cohort of ICS users has a higher
rate of LAEs than non-ICS users. LAEs are associated with ICS
use and likely to increase total cost of asthma care. Health care
decision makers should consider the LAE proﬁles and their
potential economic impact when evaluating choices for asthma
therapy.
